Danaher Corporation
Danaher Reports First Quarter 2025 Financial Results and Outlook
Summary
Danaher Corporation reported net earnings of $1.0 billion for the first quarter of 2025, or $1.32 per diluted common share, with revenues decreasing by 1.0% to $5.7 billion. Non-GAAP core revenue remained flat year-over-year. The company anticipates low-single-digit growth in non-GAAP core revenue for the second quarter and approximately 3% growth for the full year 2025. The company also provided full-year adjusted diluted net earnings per common share guidance in the range of $7.60 to $7.75.
Profitelligence Alerts
Get alerts for DHR
Be first to know when Danaher Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Danaher Corporation
Danaher Corporation is a globally recognized science and technology company specializing in the development, design, and manufacturing of diverse industrial and healthcare products. With a primary focus on innovations in diagnostics, life sciences, dental, and environmental and applied solutions, Danaher serves a multitude of industries and market sectors. Its cutting-edge diagnostic equipment aids medical professionals in delivering precise healthcare, while its life sciences tools and technologies propel biomedical research and development. The company's environmental solutions also play a key role in enhancing water quality analysis and management. Headquartered in Washington, D.C., Danaher is renowned for its strong operational culture exemplified by the Danaher Business System (DBS), which emphasizes continuous improvement and sustainable innovation. This approach has solidified Danaher's presence and influence in both developing specialized solutions and improving efficiency across global markets. The company's strategic acquisitions and consistent focus on innovation have positioned it as a leader in delivering essential solutions that drive significant improvements for healthcare, research, and industrial clients.
Official SEC Documents
Advertisement